SUBSCRIBE
SUBSCRIBE

AstraZeneca Pharmaceuticals LP

NEWS
Drug Development
AstraZeneca’s Brilinta Decreases Risk of New Stroke Events After Stroke or TIA
AstraZeneca released positive data from the Phase III THALES trial of Brilinta (ticagrelor) used twice a day with an aspirin.
July 16, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: July 15
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
July 14, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: July 3
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 3, 2020.
July 2, 2020
 · 
1 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: June 24
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
June 23, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: June 17
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
June 16, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Courtesy of Alexanderstock23/Shutterstock
Job Trends
AstraZeneca Strikes Deal with European Nations to Supply 400 Million Doses of COVID-19 Vaccine
The U.K. pharma giant struck a deal with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of the preventative medication by the end of 2020 – if it clears the clinic.
June 15, 2020
 · 
3 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: June 15
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.
June 15, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: June 8-12
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
June 12, 2020
 · 
12 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: June 12
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
June 11, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
December 30, 2025
 · 
5 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
December 23, 2025
 · 
19 min read
Press Releases
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
December 23, 2025
 · 
20 min read
Press Releases
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
December 23, 2025
 · 
19 min read
Press Releases
Niowave Expands Global Supply Agreement with AstraZeneca to Deliver Actinium-225 for Next-Generation Cancer Therapies
December 19, 2025
 · 
2 min read
Press Releases
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy
December 18, 2025
 · 
9 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
December 16, 2025
 · 
19 min read
Press Releases
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
December 16, 2025
 · 
19 min read
Press Releases
Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU
December 16, 2025
 · 
7 min read
Press Releases
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
December 10, 2025
 · 
19 min read
Load More